Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) (clinicaltrials.gov) - Sep 24, 2026 - P3 | N=450 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Jan 2034 ➔ Apr 2034 | Trial primary completion date: Jan 2034 ➔ Apr 2034
Trial completion date • Trial primary completion date • Oncology • Von Hippel-Lindau Syndrome
|